ID

13770

Descripción

Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients; ODM derived from: https://clinicaltrials.gov/show/NCT01402089

Link

https://clinicaltrials.gov/show/NCT01402089

Palabras clave

Versiones (1)
  1. 6/3/16 6/3/16 -
Subido en

6 de marzo de 2016

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY 4.0
Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Volver a los comentarios del modelo
Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Eligibility Non Small-cell Lung Cancer NCT01402089

Inglés

Eligibility Non Small-cell Lung Cancer NCT01402089

1 formularios  
Inclusion Criteria
Descripción

Inclusion Criteria

Alias
UMLS CUI
C1512693
histologically or cytologically confirmed renal-cell cancer or gastrointestinal stromal tumor (for sunitinib) or non small-cell lung cancer (for erlotinib)
Descripción

renal-cell cancer; gastrointestinal stromal tumor; non small-cell lung cancer; sunitinib; erlotinib

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0007134
UMLS CUI [2]
C0238198
UMLS CUI [3]
C0007131
UMLS CUI [4]
C1176020
UMLS CUI [5]
C1135135
both early or advanced tumor stage
Descripción

tumor stage

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1300072
indication for the therapeutic use of either sunitinib or erlotinib
Descripción

sunitinib; erlotinib

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1176020
UMLS CUI [2]
C1135135
written informed consent and willing to undergo pk-sampling
Descripción

informed consent

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0021430
patients > 18 years of age
Descripción

age

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0001779
ecog performance status or ≤2
Descripción

ecog

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1520224
adequate laboratory parameters:
Descripción

laboratory parameters

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0022885
i. serum creatinine and serum bilirubin ≤ 1.5 x uln ii. serum alt and ast ≤ 2.5 x uln (or ≤ 5 in case of liver metastases) iii. serum calcium ≤ 11,6 mg/dl (2.9 mmol/l)
Descripción

serum creatinine; serum bilirubin; alt and ast; serum calcium

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0201976
UMLS CUI [2]
C0428441
UMLS CUI [3]
C3831581
UMLS CUI [4]
C0728876
Exclusion Criteria
Descripción

Exclusion Criteria

Alias
UMLS CUI
C0680251
previous treatment with sunitinib or erlotinib
Descripción

sunitinib; erlotinib

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1176020
UMLS CUI [2]
C1135135
known hypersensitivity to trial drug or any compounds of the drug
Descripción

hypersensitivity study drugs

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C0013227
UMLS CUI [1,3]
C0008972
concurrent radiotherapy
Descripción

concurrent therapy radiotherapy

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0009429
UMLS CUI [1,2]
C1522449
concurrent systemic anticancer treatment with the exception of bisphosphonates and bevacizumab in patients with non small-cell lung cancer
Descripción

concurrent therapy cancer treatment; bisphosphonates; bevacizumab

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0009429
UMLS CUI [1,2]
C0920425
UMLS CUI [2]
C0012544
UMLS CUI [3]
C0796392
Volver a la parte superior de la página

Similar models

Eligibility Non Small-cell Lung Cancer NCT01402089

1 formularios
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
C1512693 (UMLS CUI)
renal-cell cancer; gastrointestinal stromal tumor; non small-cell lung cancer; sunitinib; erlotinib
Item
histologically or cytologically confirmed renal-cell cancer or gastrointestinal stromal tumor (for sunitinib) or non small-cell lung cancer (for erlotinib)
boolean
C0007134 (UMLS CUI [1])
C0238198 (UMLS CUI [2])
C0007131 (UMLS CUI [3])
C1176020 (UMLS CUI [4])
C1135135 (UMLS CUI [5])
tumor stage
Item
both early or advanced tumor stage
boolean
C1300072 (UMLS CUI [1])
sunitinib; erlotinib
Item
indication for the therapeutic use of either sunitinib or erlotinib
boolean
C1176020 (UMLS CUI [1])
C1135135 (UMLS CUI [2])
informed consent
Item
written informed consent and willing to undergo pk-sampling
boolean
C0021430 (UMLS CUI [1])
age
Item
patients > 18 years of age
boolean
C0001779 (UMLS CUI [1])
ecog
Item
ecog performance status or ≤2
boolean
C1520224 (UMLS CUI [1])
laboratory parameters
Item
adequate laboratory parameters:
boolean
C0022885 (UMLS CUI [1])
serum creatinine; serum bilirubin; alt and ast; serum calcium
Item
i. serum creatinine and serum bilirubin ≤ 1.5 x uln ii. serum alt and ast ≤ 2.5 x uln (or ≤ 5 in case of liver metastases) iii. serum calcium ≤ 11,6 mg/dl (2.9 mmol/l)
boolean
C0201976 (UMLS CUI [1])
C0428441 (UMLS CUI [2])
C3831581 (UMLS CUI [3])
C0728876 (UMLS CUI [4])
Item Group
C0680251 (UMLS CUI)
sunitinib; erlotinib
Item
previous treatment with sunitinib or erlotinib
boolean
C1176020 (UMLS CUI [1])
C1135135 (UMLS CUI [2])
hypersensitivity study drugs
Item
known hypersensitivity to trial drug or any compounds of the drug
boolean
C0020517 (UMLS CUI [1,1])
C0013227 (UMLS CUI [1,2])
C0008972 (UMLS CUI [1,3])
concurrent therapy radiotherapy
Item
concurrent radiotherapy
boolean
C0009429 (UMLS CUI [1,1])
C1522449 (UMLS CUI [1,2])
concurrent therapy cancer treatment; bisphosphonates; bevacizumab
Item
concurrent systemic anticancer treatment with the exception of bisphosphonates and bevacizumab in patients with non small-cell lung cancer
boolean
C0009429 (UMLS CUI [1,1])
C0920425 (UMLS CUI [1,2])
C0012544 (UMLS CUI [2])
C0796392 (UMLS CUI [3])
Volver a la parte superior de la página 

Contacto

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial